This study explores the use of hybrid cell membrane-coated nanoparticles to enhance the targeting and efficacy of treatments for Alzheimer's Disease (AD). The blood-brain barrier (BBB) poses significant challenges for therapeutic drug delivery in neurological diseases. To address this, the researchers designed a novel cell membrane coating by hybridizing platelet membranes with chemokine (C–C motif) receptor 2 (CCR2) cells, which are overexpressed to cross the BBB and target neuroinflammatory lesions. Two drugs, rapamycin and 1-Trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU), were loaded into liposomes to achieve multitargeted therapy. In a transgenic mouse model of familial AD (5xFAD), the administration of these drug-loaded hybrid cell membrane liposomes significantly reduced amyloid plaque deposition, neuroinflammation, and cognitive impairments. The results demonstrate that hybrid cell membrane-coated nanomaterials offer new opportunities for precise drug delivery and disease-specific targeting, representing a versatile platform for targeted therapy in AD.This study explores the use of hybrid cell membrane-coated nanoparticles to enhance the targeting and efficacy of treatments for Alzheimer's Disease (AD). The blood-brain barrier (BBB) poses significant challenges for therapeutic drug delivery in neurological diseases. To address this, the researchers designed a novel cell membrane coating by hybridizing platelet membranes with chemokine (C–C motif) receptor 2 (CCR2) cells, which are overexpressed to cross the BBB and target neuroinflammatory lesions. Two drugs, rapamycin and 1-Trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU), were loaded into liposomes to achieve multitargeted therapy. In a transgenic mouse model of familial AD (5xFAD), the administration of these drug-loaded hybrid cell membrane liposomes significantly reduced amyloid plaque deposition, neuroinflammation, and cognitive impairments. The results demonstrate that hybrid cell membrane-coated nanomaterials offer new opportunities for precise drug delivery and disease-specific targeting, representing a versatile platform for targeted therapy in AD.